Press release – For immediate release – 5:45 pm CET
Median Technologies meets the eligibility conditions for the PEA-PME scheme
Median Technologies (FR0011049824, ALMDT) confirms its eligibility for the PEA-PME scheme in accordance with the provisions of Articles L. 221-32-2 and D. 221-113-5 and following of the Monetary and Financial Code specifying the conditions for assessing the eligibility criteria, i.e.:
- Less than 5,000 employees,
- An annual turnover of less than 1.5 billion euros or a balance sheet total of less than 2 billion euros.
Median Technologies shares therefore continue to be included in PEA-PME accounts, which for the record benefit from the same tax advantages as the traditional stock savings plan (PEA).
Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit